FindTrial
Sign In

Interventional timing and clinical efficacy of hyperbaric oxygen therapy for patients with novel coronavirus pneumonia

Interventional timing and clinical efficacy of hyperbaric oxygen therapy for patients with novel coronavirus pneumonia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300070401
Enrollment
Unknown
Registered
2023-04-11
Start date
2023-04-15
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

novel coronavirus pneumonia (COVID-19)

Interventions

Control group:Conventional oxygen therapy
Experimental group:Hyperbaric oxygen therapy

Sponsors

Ji'nan Eighth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. All patients met the diagnostic criteria for COVID-19 in the Diagnosis and Treatment Protocol for novel Coronavirus infection (Trial version 10). 2. COVID-19 positive patients were taken to the warehouse for hyperbaric oxygen treatment after turning negative.

Exclusion criteria

Exclusion criteria: 1. Complicated with respiratory diseases such as severe emphysema, pulmonary bulla, pneumothorax, lung cancer (under application of antitumor drugs); 2. Complicated with serious underlying diseases such as heart failure, liver and kidney insufficiency; 3. Can not cooperate with hyperbaric oxygen therapy; 4. Poor treatment compliance.

Design outcomes

Primary

MeasureTime frame
Chest CT;Determination of exhaled nitric oxide;Blood routine;Leicester Cough Questionnaire, LCQ;—

Countries

China

Contacts

Public ContactCai Renping

Ji'nan Eighth People's Hospital

cairenping@163.com+86 15006820725

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026